Kinase News and Research

RSS

Fat tissue could be a source of diabetes, shows new research

A new study by Australian researchers, out today, is challenging what we know about the causes of diabetes. The new research points to fat tissue as a source of disease, and widens our understanding beyond the traditional focus on liver and pancreas as the main culprits.

12 Oct 2018

Top journal publishes special issue on deep learning for drug discovery and biomarker development

While the many concepts in artificial intelligence date back to the 20th century, the revolution in deep learning started around 2014-2015 when AI systems started outperforming humans in many tasks ranging from video games and image recognition to autonomous driving.

11 Oct 2018

Study shows that one amino acid may produce short-term lowering of glucose levels

Type 2 diabetes is driven by many metabolic pathways, with some pathways driven by amino acids, the molecular building blocks for proteins.

11 Oct 2018

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs, a study to be presented at ESMO 2018 reported.

10 Oct 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem, Inc., focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the National Comprehensive Cancer Network added COPIKTRA (duvelisib) capsules to the Clinical Practice Guidelines in Oncology (NCCN Guidelines) for follicular lymphoma.

8 Oct 2018

Identification of wheat resistance gene promotes durable solution for controlling food security threat

Identification of the wheat Yr15 resistance gene promotes a durable solution for controlling yellow rust, a major threat to food security for millions of people, believes an international research group led by Natural Resources Institute Finland, the Institute of Biotechnology at the University of Helsinki, and the University of Haifa.

8 Oct 2018

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.

4 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, as part of the agency's Small Business Innovation Research Program.

27 Sep 2018

New cell-based profiling service from RBC and Promega

A new cell-based profiling service for drug discovery has been announced by RBC and Promega Corporation.

From Promega Corporation 27 Sep 2018

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

VRK1 protein may enable cancer cells to colonize new areas of the body during metastasis

Sometimes negative results can point researchers in the right direction. In results published in PLOS ONE on September 4, 2018, scientists at the Medical University of South Carolina examined a protein called vaccinia-related kinase 1 that they hypothesized was important for metastasis. They found that, rather than causing cancer cells to migrate and invade, VRK1 over-expression had the opposite effect.

26 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Researchers identify key step in how plant cells respond to pathogens

Just like humans, plants have an immune system that helps them fight off infections. Plant immunity has some important differences: they don't make antibodies and can't fight off the same bug more quickly months or years later.

18 Sep 2018

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

Many eye diseases, including diabetic retinopathy and macular degeneration, exhibit increased permeability of blood vessels in the macular (central) portion of the retina leading to abnormal fluid accumulation and vision loss.

14 Sep 2018

Kinase News and Research

Fat tissue could be a source of diabetes, shows new research

Top journal publishes special issue on deep learning for drug discovery and biomarker development

Study shows that one amino acid may produce short-term lowering of glucose levels

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Identification of wheat resistance gene promotes durable solution for controlling food security threat

MD Anderson and Cyclacel announce strategic alliance to evaluate novel drugs for hematological malignancies

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

New cell-based profiling service from RBC and Promega

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

VRK1 protein may enable cancer cells to colonize new areas of the body during metastasis

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Researchers identify key step in how plant cells respond to pathogens

Study: aPKC inhibitors may provide new therapeutic option for blinding eye diseases

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News